WS Investor
09 Mar 2026, 22:31
Bristol Myers Squibb announced positive interim Phase 3 results from the SUCCESSOR-2 study evaluating oral mezigdomide in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
The study showed that the MeziKd regimen delivered a statistically significant and clinically meaningful improvement in progression-free survival compared with treatment using carfilzomib and dexamethasone alone. Safety outcomes were consistent with the known profile of the therapy, and patients will continue to be monitored for long-term survival and safety outcomes.
The results represent the first successful Phase 3 trial for mezigdomide and the second positive Phase 3 study within Bristol Myers Squibb’s CELMoD program, which is based on targeted protein degradation technology designed to treat difficult blood cancers. Data from the trial will be presented at a future medical conference and shared with regulatory authorities.
Source: Business Wire
The study showed that the MeziKd regimen delivered a statistically significant and clinically meaningful improvement in progression-free survival compared with treatment using carfilzomib and dexamethasone alone. Safety outcomes were consistent with the known profile of the therapy, and patients will continue to be monitored for long-term survival and safety outcomes.
The results represent the first successful Phase 3 trial for mezigdomide and the second positive Phase 3 study within Bristol Myers Squibb’s CELMoD program, which is based on targeted protein degradation technology designed to treat difficult blood cancers. Data from the trial will be presented at a future medical conference and shared with regulatory authorities.
Source: Business Wire